Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.

Vantage logo

The ipatasertib curate’s egg

Roche’s Akt inhibitor’s first pivotal result, in first-line prostate cancer, is at best a partial success and at worst an irrelevance.